美国大型医疗系统青少年女性中无指征宫颈癌筛查的现状分析
本研究基于美国一大型多医院医疗系统2012至2018年的横断面数据,分析了13至20岁青少年女性中无指征宫颈癌筛查的趋势及操作者因素。共纳入118名操作者和794名女性,900次筛查结果中90%为无指征。无指征细胞学筛查率从2012年的12.6/1000次就诊降至2018年的8.5/1000次就诊,学术机构低于社区机构。
要点
- 青少年中90%的宫颈癌筛查无指征,77%细胞学结果为阴性。
- 无指征筛查率7年间下降33%,但末年度仍有58次无指征筛查。
- 学术机构无指征筛查率显著低于社区机构(IRR 0.43,P<.01)。
核心结论
- 尽管无指征宫颈癌筛查率显著下降,但指南不依从现象持续存在,需加强循证策略以提高指南传播与依从性。
研究设计与样本
- 横断面研究,纳入美国最大医疗系统内2012年1月1日至2018年12月31日期间13至20岁接受宫颈癌筛查的患者,共118名操作者和794名女性、900次筛查结果。
主要发现
- 900次筛查结果中90%无指征,其中87%为无指征细胞学检查,14%为无指征HPV检测。
- 25名患者在21岁前接受了至少3次无指征细胞学检查。
- 77%的细胞学结果为未见上皮内病变或恶性。
- 共进行52例侵入性诊断或治疗操作(49例阴道镜和3例锥切),其中45例(87%)发生在无指征筛查之后。
- 2012至2018年间,无指征细胞学筛查发生率从12.6/1000次就诊降至8.5/1000次就诊,下降33%。
关键数值与推荐
- 当前共识推荐:免疫功能正常的青少年女性在21岁前不应启动宫颈癌筛查。
- 20至24岁女性新发宫颈癌率极低,为0.8/10万。
- 及时接种HPV疫苗可使28岁时宫颈癌发病率降至4/10万。
- 21岁前筛查未显示在降低癌症风险或改善结局方面有明确获益。
临床怎么用
- 临床应避免对21岁以下免疫功能正常女性进行宫颈癌筛查,并关注社区机构中指南依从性的提升。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current consensus recommendations are to not initiate cervical cancer screening for immunocompetent adolescent females before 21 years of age. This is in part because of the very low rate of 0.8 per 100,000 new cervical cancer cases diagnosed among women aged between 20 to 24 years. Timely human papillomavirus vaccination further decreases the incidence of cervical cancer to 4 cases per 100,000 persons by the age of 28 years. Screening before 21 years of age has demonstrated no clear benefit in cancer risk reduction or outcomes. In addition, unindicated screening among adolescents can lead to patient harm and increasing costs to the healthcare system. OBJECTIVE: It is important to assess the rates of overutilization of cervical cancer screening and to identify areas where improvements have occurred and where further opportunities exist. This study aimed to assess the trends over time and the practice and provider factors associated with unindicated cervical cancer screening tests in adolescent females within the largest healthcare system in the state. STUDY DESIGN: Cross-sectional data from patients aged 13 to 20 years who underwent cervical cancer screening between January 1, 2012, and December 31, 2018, across a large multihospital health system were reviewed. All cervical cancer screening results were included. The incidence rate of unindicated screening was analyzed over 6-month intervals using the Poisson regression analysis. RESULTS: The study included data from 118 providers and 794 women. Among the 900 screening results, most (90%) were unindicated: 87% with unindicated cytology testing alone and 14% with unindicated human papillomavirus testing. Screening tests were collected from patients aged 13 to 20 years, many of whom had multiple unindicated cytology tests, with 25 patients having ≥3 tests before the age of 21 years. Most results of cytology testing were negative for intraepithelial lesion or malignancy (77%). Moreover, 52 invasive diagnostic or therapeutic procedures (49 colposcopies and 3 conizations) were performed, of which 45 (87%) followed an unindicated screening test. Between 2012 and 2018, the incidence rate of unindicated cytology decreased by 33% (12.6 to 8.5 unindicated cytology per 1000 encounters). The incidence rate of unindicated screening was lower in the academic setting than in the community setting (incidence rate ratio, 0.43; P<.01). Even with decreases in the overall rates of unindicated screening throughout the study period, there were still 58 unindicated screening tests performed in the final year of this study. CONCLUSION: Despite substantial reductions in unindicated screening for women aged <21 years, there remained areas for improvement. Our data reflected practices of guideline nonadherence up to 7 years after the 2012 guideline. Now, with a new series of changes to the guidelines, which may be even more challenging for patients and providers, it is more important than ever to utilize evidence-based strategies to improve guideline dissemination and adherence.
引用
- Hosier H, Sheth SS, Oliveira CR, et al. Unindicated cervical cancer screening in adolescent females within a large healthcare system in the United States. Am J Obstet Gynecol. 2021. PMID: 34256029. doi:10.1016/j.ajog.2021.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。